We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Adjuvant Chemotherapy Unnecessary for Early Breast Cancer

By HospiMedica International staff writers
Posted on 14 Jun 2018
Print article
Image: The Oncotype Dx tests 21 genes related to breast cancer (Photo courtesy of NEJM).
Image: The Oncotype Dx tests 21 genes related to breast cancer (Photo courtesy of NEJM).
A new study found no difference in disease-free survival of women with axillary node-negative breast cancer (BC) treated with endocrine therapy alone, or with a combination of endocrine therapy with chemotherapy.

Researchers at the Montefiore Einstein Center for Cancer Care (MECCC; New York, NY, USA), Northwestern University (NU; Chicago, IL, USA), and other institutions conducted a prospective trial involving 10,273 women with hormone-receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative, axillary node-negative breast cancer, as assessed by the Genomic Health (Redwood City, CA, USA) Oncotype Dx test.

In all, 9,719 eligible patients were available for follow-up information, of which 69% had a midrange Oncotype Dx test recurrence score of 11-25. The women in the midrange group were then randomly assigned to receive either adjuvant chemoendocrine therapy or endocrine therapy alone. The trial was designed so as to show non-inferiority of endocrine therapy alone for invasive disease–free survival, defined as freedom from invasive disease recurrence, second primary cancer, or death.

The results revealed that at nine years follow-up, the two treatment groups had similar rates of invasive disease–free survival (83.3% in the endocrine-therapy group and 84.3% in the chemoendocrine-therapy group), freedom from disease recurrence at a distant regional site (94.5% and 95%, respectively), at a local site (92.2% and 92.9%), as well as overall survival (93.9% and 93.8%). A chemotherapy benefit was found only in women 50 years of age or younger with a recurrence score of 16-25. The study was published on June 3, 2018, in the New England Journal of Medicine (NEJM).

“In terms of the big picture and the impact on care, application of this test in clinical practice will spare an estimated 70% of patients and limit chemotherapy to the 30% who may benefit from it,” said lead author Joseph Sparano, MD, associate director for clinical research at MECCC. “A very important finding was that … we found an interaction between age and recurrence score. Women younger than 50 years with a recurrence score of 16 to 25 received some benefit from chemotherapy. This information can drive some women with recurrence scores in this range to accept chemotherapy.”

The Oncotype DX genomic test analyzes the activity of 21 genes to provide prognostic information in hormone receptor–positive breast cancer, with a recurrence score that ranges from 0 to 100. Patients who obtain a high score (defined as 26 or higher) are considered to be at high risk for relapse; patients who obtain a low score (0-10) are considered to have a very low rate of distant recurrence.

Related Links:
Montefiore Einstein Center for Cancer Care
Northwestern University
Genomic Health

Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Color Doppler Ultrasound System
KC20

Print article

Channels

Critical Care

view channel
Image: Researchers have developed an advanced shear-thinning hydrogel for aneurysm repair (Photo courtesy of TIBI)

New Hydrogel Features Enhanced Capabilities for Treating Aneurysms and Halting Progression

Aneurysms can develop in blood vessels in different body areas, often as a result of atherosclerosis, infections, inflammatory diseases, and other risk factors. These conditions lead to chronic inflammation,... Read more

Surgical Techniques

view channel
Image: The living replacement knee will be tested in clinical trials within five years (Photo courtesy of ARPA-H)

Living Knee Replacement to Revolutionize Osteoarthritis Treatment

Osteoarthritis is the most prevalent type of arthritis, characterized by the progressive deterioration of cartilage, or the protective tissue covering the bone ends, resulting in pain, stiffness, and impaired... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The new eye-safe laser technology can diagnose traumatic brain injury (Photo courtesy of 123RF)

Novel Diagnostic Hand-Held Device Detects Known Biomarkers for Traumatic Brain Injury

The growing need for prompt and efficient diagnosis of traumatic brain injury (TBI), a major cause of mortality globally, has spurred the development of innovative diagnostic technologies.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.